SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryClinical TrialClinical Development

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169366

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169366

Omics-Based Clinical Trials Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 280 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Description

Table of Contents

Introduction

Omics-based clinical trials are changing how new medicines are tested, matching patients to therapies through genomic, proteomic, transcriptomic and metabolomic profiling rather than broad clinical criteria alone. Sponsors use these molecular readouts to select participants, stratify cohorts, confirm mechanisms of action and identify responders earlier in development. In 2026, the market is valued at US$38.32 Bn and is projected to reach US$65.67 Bn by 2033, registering a CAGR of 8.00%. This growth reflects a steady move toward precision medicine across the drug development pipeline, with molecular data now treated as a core trial asset rather than an exploratory add-on. Research organizations, central laboratories and sequencing specialists are integrating sample handling, testing and analytics into single service offerings. At the same time, sponsors are under pressure to reduce late-stage failure rates, and omics-guided enrollment offers a practical route to smaller, more targeted studies with clearer efficacy signals. Together, these shifts are making omics a routine feature of trial planning rather than a specialist exception.

Market Insights

The market is structured across three segmentation dimensions: phase, study design and indication. By phase, activity spans Phase I, Phase II, Phase III and Phase IV studies, with omics tools used for early safety and dose work as well as for confirming benefit in larger populations and monitoring outcomes after approval. Study designs include interventional, observational and expanded access programs, giving sponsors flexibility in how molecular data are collected and applied. Indications covered include oncology, inflammation and autoimmune disorders, cardiovascular disease, neurology, infectious diseases and other therapeutic areas. A clear trend is the shift from single-gene tests toward multi-omics profiling combined with artificial intelligence, allowing researchers to connect several layers of biological data within one study. Liquid biopsy, single-cell analysis and spatial biology are also moving out of discovery labs and into formal trial protocols. Service providers are responding by building laboratory networks in Asia Pacific to support sample processing closer to fast-growing patient populations and trial sites.

Drivers

Two forces are central to market expansion. The first is the rise of precision medicine and targeted therapies, which carries a high impact over the long term. As more drug programs are designed around specific molecular alterations, sponsors need omics data to find eligible patients, prove that a therapy works on its intended target and support companion diagnostic development. The second driver is the falling cost of sequencing combined with AI-based analytics, rated as high impact in the medium term. Lower per-sample costs make it practical to profile larger cohorts, while machine learning tools turn complex datasets into usable insights for trial design and patient selection. These drivers do operate against meaningful headwinds. High costs and data complexity remain a high-impact, short-term restraint, as multi-layer datasets demand specialized infrastructure and skilled staff. Data privacy and regulatory hurdles add a medium-impact, medium-term constraint, particularly in Europe and Asia Pacific, where rules on genetic data handling and cross-border transfer can slow study start-up.

Business Opportunity

The most attractive opportunity lies in multi-omics and AI-driven trial design, which opens a premium revenue pool for providers able to combine advanced laboratory capability with strong analytics. Sponsors increasingly want partners who can integrate genomic, proteomic and other molecular layers, interpret them quickly and feed the results directly into enrollment decisions and adaptive protocols. Providers that offer end-to-end services, from sample collection through data interpretation, are positioned to capture higher-value contracts and longer relationships with drug developers. A second opportunity comes from trial capacity in Asia Pacific, which creates a volume revenue pool. Large and diverse patient populations, expanding hospital research networks and growing local laboratory infrastructure make the region attractive for recruiting participants at scale. Organizations that invest early in regional laboratories, data management systems and regulatory know-how can support global sponsors seeking faster enrollment. Combining premium analytical services with high-volume regional capacity offers a balanced route to sustained revenue growth across the forecast period.

Region Analysis

North America leads the market with a 38.0% share in 2026, supported by a dense base of drug developers, research organizations, academic medical centers and sequencing providers. The region benefits from established reimbursement for molecular testing and a regulatory environment familiar with biomarker-driven study designs. Europe represents a significant market built on strong academic research and coordinated clinical networks, though data privacy rules and regulatory requirements around genetic information can lengthen study timelines. Asia Pacific is the fastest-growing region, advancing at a 9.8% CAGR through 2033. Expanding trial capacity, large treatment-naive patient pools and new laboratory networks are drawing global sponsors to the region, even as regulatory hurdles vary by country. Latin America offers growing potential as sponsors look for diverse populations and cost-efficient recruitment, with research infrastructure gradually improving in major urban centers. The Middle East and Africa remain smaller contributors, yet investment in genomic research programs and specialty hospitals is building a foundation for wider participation in omics-guided studies.

Key Players

  • IQVIA
  • Thermo Fisher Scientific (PPD)
  • ICON
  • Labcorp
  • Parexel
  • Syneos Health
  • Medpace
  • Charles River Laboratories
  • Illumina
  • QIAGEN

Segmentation

By Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Study Design:

  • Interventional
  • Observational
  • Expanded Access

By Indication:

  • Oncology
  • Inflammation & Autoimmune
  • Cardiovascular
  • Neurology
  • Infectious Diseases
  • Others

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Omics-Based Clinical Trials Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Omics-Based Clinical Trials Market Outlook, 2020 - 2033

  • 3.1. Global Omics-Based Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2020-2033
    • 3.1.1. Phase I
    • 3.1.2. Phase II
    • 3.1.3. Phase III
    • 3.1.4. Phase IV
  • 3.2. Global Omics-Based Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2020-2033
    • 3.2.1. Interventional
    • 3.2.2. Observational
    • 3.2.3. Expanded Access
  • 3.3. Global Omics-Based Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 3.3.1. Oncology
    • 3.3.2. Inflammation & Autoimmune
    • 3.3.3. Cardiovascular
    • 3.3.4. Neurology
    • 3.3.5. Infectious Diseases
    • 3.3.6. Others
  • 3.4. Global Omics-Based Clinical Trials Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Omics-Based Clinical Trials Market Outlook, 2020 - 2033

  • 4.1. North America Omics-Based Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2020-2033
    • 4.1.1. Phase I
    • 4.1.2. Phase II
    • 4.1.3. Phase III
    • 4.1.4. Phase IV
  • 4.2. North America Omics-Based Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2020-2033
    • 4.2.1. Interventional
    • 4.2.2. Observational
    • 4.2.3. Expanded Access
  • 4.3. North America Omics-Based Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 4.3.1. Oncology
    • 4.3.2. Inflammation & Autoimmune
    • 4.3.3. Cardiovascular
    • 4.3.4. Neurology
    • 4.3.5. Infectious Diseases
    • 4.3.6. Others
  • 4.4. North America Omics-Based Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 4.4.2. U.S. Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 4.4.3. U.S. Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 4.4.4. Canada Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 4.4.5. Canada Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 4.4.6. Canada Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Omics-Based Clinical Trials Market Outlook, 2020 - 2033

  • 5.1. Europe Omics-Based Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2020-2033
    • 5.1.1. Phase I
    • 5.1.2. Phase II
    • 5.1.3. Phase III
    • 5.1.4. Phase IV
  • 5.2. Europe Omics-Based Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2020-2033
    • 5.2.1. Interventional
    • 5.2.2. Observational
    • 5.2.3. Expanded Access
  • 5.3. Europe Omics-Based Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 5.3.1. Oncology
    • 5.3.2. Inflammation & Autoimmune
    • 5.3.3. Cardiovascular
    • 5.3.4. Neurology
    • 5.3.5. Infectious Diseases
    • 5.3.6. Others
  • 5.4. Europe Omics-Based Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 5.4.2. Germany Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 5.4.3. Germany Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 5.4.4. Italy Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 5.4.5. Italy Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 5.4.6. Italy Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 5.4.7. France Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 5.4.8. France Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 5.4.9. France Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 5.4.10. U.K. Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 5.4.11. U.K. Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 5.4.12. U.K. Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 5.4.13. Spain Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 5.4.14. Spain Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 5.4.15. Spain Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 5.4.16. Russia Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 5.4.17. Russia Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 5.4.18. Russia Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 5.4.19. Rest of Europe Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 5.4.20. Rest of Europe Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 5.4.21. Rest of Europe Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Omics-Based Clinical Trials Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Omics-Based Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2020-2033
    • 6.1.1. Phase I
    • 6.1.2. Phase II
    • 6.1.3. Phase III
    • 6.1.4. Phase IV
  • 6.2. Asia Pacific Omics-Based Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2020-2033
    • 6.2.1. Interventional
    • 6.2.2. Observational
    • 6.2.3. Expanded Access
  • 6.3. Asia Pacific Omics-Based Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 6.3.1. Oncology
    • 6.3.2. Inflammation & Autoimmune
    • 6.3.3. Cardiovascular
    • 6.3.4. Neurology
    • 6.3.5. Infectious Diseases
    • 6.3.6. Others
  • 6.4. Asia Pacific Omics-Based Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 6.4.2. China Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 6.4.3. China Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 6.4.4. Japan Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 6.4.5. Japan Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 6.4.6. Japan Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 6.4.7. South Korea Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 6.4.8. South Korea Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 6.4.9. South Korea Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 6.4.10. India Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 6.4.11. India Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 6.4.12. India Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 6.4.13. Southeast Asia Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 6.4.14. Southeast Asia Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 6.4.15. Southeast Asia Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 6.4.16. Rest of SAO Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 6.4.17. Rest of SAO Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 6.4.18. Rest of SAO Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Omics-Based Clinical Trials Market Outlook, 2020 - 2033

  • 7.1. Latin America Omics-Based Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2020-2033
    • 7.1.1. Phase I
    • 7.1.2. Phase II
    • 7.1.3. Phase III
    • 7.1.4. Phase IV
  • 7.2. Latin America Omics-Based Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2020-2033
    • 7.2.1. Interventional
    • 7.2.2. Observational
    • 7.2.3. Expanded Access
  • 7.3. Latin America Omics-Based Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 7.3.1. Oncology
    • 7.3.2. Inflammation & Autoimmune
    • 7.3.3. Cardiovascular
    • 7.3.4. Neurology
    • 7.3.5. Infectious Diseases
    • 7.3.6. Others
  • 7.4. Latin America Omics-Based Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 7.4.2. Brazil Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 7.4.3. Brazil Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 7.4.4. Mexico Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 7.4.5. Mexico Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 7.4.6. Mexico Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 7.4.7. Argentina Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 7.4.8. Argentina Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 7.4.9. Argentina Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 7.4.10. Rest of LATAM Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 7.4.11. Rest of LATAM Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 7.4.12. Rest of LATAM Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Omics-Based Clinical Trials Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Omics-Based Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2020-2033
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
    • 8.1.4. Phase IV
  • 8.2. Middle East & Africa Omics-Based Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2020-2033
    • 8.2.1. Interventional
    • 8.2.2. Observational
    • 8.2.3. Expanded Access
  • 8.3. Middle East & Africa Omics-Based Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 8.3.1. Oncology
    • 8.3.2. Inflammation & Autoimmune
    • 8.3.3. Cardiovascular
    • 8.3.4. Neurology
    • 8.3.5. Infectious Diseases
    • 8.3.6. Others
  • 8.4. Middle East & Africa Omics-Based Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 8.4.2. GCC Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 8.4.3. GCC Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 8.4.4. South Africa Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 8.4.5. South Africa Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 8.4.6. South Africa Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 8.4.7. Egypt Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 8.4.8. Egypt Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 8.4.9. Egypt Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 8.4.10. Nigeria Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 8.4.11. Nigeria Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 8.4.12. Nigeria Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
    • 8.4.13. Rest of Middle East Omics-Based Clinical Trials Market Outlook, by Phase, 2020-2033
    • 8.4.14. Rest of Middle East Omics-Based Clinical Trials Market Outlook, by Study Design, 2020-2033
    • 8.4.15. Rest of Middle East Omics-Based Clinical Trials Market Outlook, by Indication, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. IQVIA
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Thermo Fisher Scientific (PPD)
    • 9.4.3. ICON
    • 9.4.4. Labcorp
    • 9.4.5. Parexel
    • 9.4.6. Syneos Health
    • 9.4.7. Medpace
    • 9.4.8. Charles River Laboratories
    • 9.4.9. Illumina
    • 9.4.10. QIAGEN

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!